Non-surgical locoregional therapies alone or in combination with systemic therapy in patients with hepatocellular carcinoma Review


Authors: Chami, P.; Jarnagin, W.; Abou-Alfa, G. K.; Harding, J.; Kim, N.; Lin, H.; El Homsi, M.; Crane, C.; Hajj, C.
Review Title: Non-surgical locoregional therapies alone or in combination with systemic therapy in patients with hepatocellular carcinoma
Abstract: Simple Summary: Ablation, arterially directed therapies and external beam radiation therapy are among the locoregional therapies considered for patients with hepatocellular carcinoma (HCC) who are ineligible for transplant or resection or as bridging therapy prior to transplant. Combinations of locoregional therapies along with systemic therapies constitute a growing area of interest with the objective of attaining superior therapeutic outcomes. We present herein an up-to-date review of the current and developing treatment modalities in this regard for HCC. Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the third-leading cause of cancer-related deaths worldwide. Curative intent treatment options for patients with HCC include liver transplantation, resection and ablation of small lesions. Other potentially curative therapies include cryoablation, microwave ablation and percutaneous alcohol injection. For locally advanced disease, different arterially directed therapies including transarterial chemoembolization and selective internal radiation therapy, plus external beam radiation including three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, stereotactic body radiation therapy and proton beam therapy, are available or studied. Systemic therapies based on checkpoint inhibitors and tyrosine kinase inhibitors are available for the management of metastatic HCC and sometimes for locally advanced disease. Combinations of locoregional therapies with systemic drugs are currently the subject of several clinical trials.
Journal Title: Cancers
Volume: 15
Issue: 6
ISSN: 2072-6694
Publisher: MDPI  
Date Published: 2023-03-02
Start Page: 1748
Language: English
DOI: 10.3390/cancers15061748
PROVIDER: EBSCOhost
PROVIDER: cinahl
PMCID: PMC10046599
PUBMED: 36980634
DOI/URL:
Notes: Accession Number: 162751147 -- Entry Date: In Process -- Revision Date: 20230403 -- Publication Type: Article -- Journal Subset: Biomedical; Continental Europe; Europe -- NLM UID: 101526829. -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Joseph Harding
    250 Harding
  2. Ghassan Abou-Alfa
    568 Abou-Alfa
  3. William R Jarnagin
    903 Jarnagin
  4. Carla Hajj
    164 Hajj
  5. Christopher   Crane
    201 Crane
  6. Nathaniel Tae-Sik Kim
    10 Kim